Literature DB >> 16091055

Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis.

S Sjöstedt1, R Befrits, A Sylvan, C Harthon, L Jörgensen, L Carling, S Modin, A Stubberöd, E Toth, T Lind.   

Abstract

BACKGROUND: On-demand therapy with esomeprazole is effective for long-term treatment of non-erosive gastro-oesophageal reflux disease, but it has not been evaluated in erosive gastro-oesophageal reflux disease. AIMS: To compare endoscopic and symptomatic remission over a 6-month period when patients with healed erosive gastro-oesophageal reflux disease are treated with esomeprazole 20 mg, either once daily or on-demand.
METHODS: Patients with verified erosive reflux oesophagitis of Los Angeles grades A-D were enrolled. Following 4-8 weeks treatment with esomeprazole 40 mg daily, those who were endoscopically healed and had symptom control during the last week were randomized to maintenance therapy for 6 months with esomeprazole 20 mg, taken either once daily or on-demand.
RESULTS: Of 539 enrolled patients, 494 (91%) were healed at 8 weeks and 477 were randomized to maintenance therapy with esomeprazole 20 mg, 243 once daily and 234 on-demand. After once daily treatment, 81% of patients were still in remission at 6 months, compared with only 58% who took on-demand treatment (P < 0.0001). A difference in remission was found irrespective of baseline grade of oesophagitis, but it was more pronounced for the more severe grades. There was no difference in overall symptomatic remission between the two treatments, although heartburn was significantly more prevalent in the on-demand group.
CONCLUSIONS: Once daily esomeprazole 20 mg was better than that taken on-demand for maintaining healed erosive oesophagitis, regardless of baseline Los Angeles grade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091055     DOI: 10.1111/j.1365-2036.2005.02553.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.

Authors:  Rickard Ekesbo; Svante Sjöstedt; Heléne Sörngård
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  The Indications, Applications, and Risks of Proton Pump Inhibitors.

Authors:  Joachim Mössner
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

4.  On-demand PPI therapy in GERD.

Authors:  Fabio Pace; Gabriele Bianchi Porro
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

5.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con.

Authors:  Lucía C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

6.  Comparison of Direct Medical Care Costs Between Erosive Reflux Disease and Non-erosive Reflux Disease in Korean Tertiary Medical Center.

Authors:  Pyoung Ju Seo; Nayoung Kim; Jane C Oh; Byoung Hwan Lee; Cheol Min Shin; Seungchul Suh; Hyunkyung Park; Ryoung Hee Nam; Jin A Cha; Young Soo Park; Dong Ho Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-07-27       Impact factor: 4.924

Review 7.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease.

Authors:  Jung Ho Park; Hyojin Park; Dong Ho Lee; In Kyung Sung
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

9.  Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

Authors:  D G Morgan; M F J O'Mahony; W F O'Mahony; J Roy; F Camacho; J Dinniwell; G L A Horbay; F A Husein-Bhabha
Journal:  Can J Gastroenterol       Date:  2007-12       Impact factor: 3.522

10.  A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori-Negative Primary Care Patients with Dyspepsia in Japan.

Authors:  Tomoari Kamada; Yoshinori Fujimura; Kensuke Gotoh; Hiroshi Imamura; Noriaki Manabe; Hiroaki Kusunoki; Kazuhiko Inoue; Akiko Shiotani; Jiro Hata; Ken Haruma
Journal:  Gut Liver       Date:  2012-12-05       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.